HYBIO(SZ:300199) Zheng Quan Zhi Xing·2025-08-22 23:19Core Viewpoint - Han Yu Pharmaceutical (300199) reported significant growth in its 2025 mid-year financial results, with total revenue reaching 549 million yuan, a year-on-year increase of 114.86%, and a net profit of 145 million yuan, up 1504.3% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 549 million yuan, compared to 256 million yuan in the same period of 2024, reflecting a growth of 114.86% [1] - The net profit for the first half of 2025 was 145 million yuan, a substantial increase from a loss of 10.36 million yuan in the previous year, marking a growth of 1504.3% [1] - The gross profit margin improved to 62.46%, up 3.96% year-on-year, while the net profit margin reached 26.3%, a significant increase of 713.06% [1] - Selling, administrative, and financial expenses totaled 148 million yuan, accounting for 27.02% of revenue, a decrease of 57.29% year-on-year [1] - Earnings per share rose to 0.16 yuan, compared to a loss of 0.01 yuan in the previous year, representing a growth of 1700.0% [1] Cash Flow and Debt - Cash and cash equivalents increased by 403.93% to 372 million yuan, attributed to bank loans received during the reporting period [1] - The current ratio stood at 0.48, indicating rising short-term debt pressure [1] - Interest-bearing liabilities increased by 15.43% to 2.06 billion yuan [1] Investment and Projects - The company has seen a 39.22% increase in accounts receivable due to higher revenue [2] - Long-term equity investments decreased by 56.59% due to recognized investment losses [2] - Construction in progress rose by 145.59% due to an increase in engineering projects [3] - The project HY3003, a collaboration utilizing peptide chip technology for weight loss indications, has completed preclinical candidate screening and is now in the raw material drug trial phase [12]